Cargando…

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial

OBJECTIVE: To assess outcomes for patients treated with interferon beta-1b immediately after clinically isolated syndrome (CIS) or after a short delay. METHODS: Participants in BENEFIT (Betaferon/Betaseron in Newly Emerging MS for Initial Treatment) were randomly assigned to receive interferon beta-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kappos, Ludwig, Edan, Gilles, Freedman, Mark S., Montalbán, Xavier, Hartung, Hans-Peter, Hemmer, Bernhard, Fox, Edward J., Barkhof, Frederik, Schippling, Sven, Schulze, Andrea, Pleimes, Dirk, Pohl, Christoph, Sandbrink, Rupert, Suarez, Gustavo, Wicklein, Eva-Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027814/ https://www.ncbi.nlm.nih.gov/pubmed/27511182 http://dx.doi.org/10.1212/WNL.0000000000003078

Ejemplares similares

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
por: Edan, G, et al.
Publicado: (2014)

Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis
por: Penner, Iris-Katharina, et al.
Publicado: (2012)

Molecular mechanism underlying the impact of vitamin D on disease activity of MS
por: Munger, Kassandra L, et al.
Publicado: (2014)

Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis
por: Freedman, MS, et al.
Publicado: (2012)

MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome
por: Nielsen, Jessica M, et al.
Publicado: (2009)

Correction: Prognostic implications of a carefully performed neurological assessment in patients with a first event suggestive of multiple sclerosis
por: Nielsen, Jessica M, et al.
Publicado: (2011)

Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial
por: Schippling, Sven, et al.
Publicado: (2016)

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
por: Cohen, Jeffrey A, et al.
Publicado: (2016)

Predictors of disease activity in 857 patients with MS treated with interferon beta-1b
por: Hartung, Hans-Peter, et al.
Publicado: (2015)

Variability in detection and quantification of interferon β-1b–induced neutralizing antibodies
por: Hartung, Hans-Peter, et al.
Publicado: (2012)

Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD)
por: Gernert, Jonathan A., et al.
Publicado: (2022)

Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis
por: van den Elskamp, I. J., et al.
Publicado: (2010)

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
por: Barkhof, Frederik, et al.
Publicado: (2019)

Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study
por: Freedman, Mark S., et al.
Publicado: (2014)

Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes
por: De Stefano, Nicola, et al.
Publicado: (2014)

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions
por: Elliott, Colm, et al.
Publicado: (2018)

MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study
por: Fox, Robert J., et al.
Publicado: (2014)

Dimethyl cis-4-hydroxymethylpiperidine-2,6-dicarboxylate
por: Hartung, Jens, et al.
Publicado: (2010)

New immunopathologic insights into multiple sclerosis
por: Hemmer, Bernhard, et al.
Publicado: (2003)

Strategy for identification of cis-dihydrodiendiol-degrading dehydrogenases in E. coli BW25113
por: Wissner, Julian L., et al.
Publicado: (2020)

Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study
por: Giovannoni, Gavin, et al.
Publicado: (2023)

The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study
por: Freedman, Mark S, et al.
Publicado: (2017)

Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta‐1a
por: Battaglini, Marco, et al.
Publicado: (2022)

Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis
por: Elliott, Colm, et al.
Publicado: (2019)

The spatio-temporal relationship between white matter lesion volume changes and brain atrophy in clinically isolated syndrome and early multiple sclerosis
por: Mattiesing, Rozemarijn M., et al.
Publicado: (2022)

The spatio-temporal relationship between concurrent lesion and brain atrophy changes in early multiple sclerosis: A post-hoc analysis of the REFLEXION study
por: Gentile, Giordano, et al.
Publicado: (2023)

Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis
por: Radue, Ernst-Wilhelm, et al.
Publicado: (2015)

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial
por: Kappos, Ludwig, et al.
Publicado: (2021)

No consensus about consensus?
por: Kappos, Ludwig
Publicado: (2021)

Combined Treatment With Pembrolizumab and Allogenic BK Virus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Case Report
por: Wicklein, Rebecca, et al.
Publicado: (2021)

Association of the retinal vasculature, intrathecal immunity, and disability in multiple sclerosis
por: Noll, Christina, et al.
Publicado: (2022)

Functional Evolution of a cis-Regulatory Module
por: Ludwig, Michael Z, et al.
Publicado: (2005)

MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice
por: Sastre-Garriga, Jaume, et al.
Publicado: (2020)

Optical coherence tomography in multiple sclerosis: A 3‐year prospective multicenter study
por: Paul, Friedemann, et al.
Publicado: (2021)

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study
por: Cohen, Jeffrey A, et al.
Publicado: (2018)

OncoCis: annotation of cis-regulatory mutations in cancer
por: Perera, Dilmi, et al.
Publicado: (2014)

Dynamics of Retinal Vessel Loss After Acute Optic Neuritis in Patients With Relapsing Multiple Sclerosis
por: Aly, Lilian, et al.
Publicado: (2022)

Induction Therapy for Patients with Multiple Sclerosis: Why? When? How?
por: Edan, Gilles, et al.
Publicado: (2013)

Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients?
por: Edan, Gilles, et al.
Publicado: (2023)

Making better use of our brain MRI research data
por: Barkhof, Frederik
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_f3c2hmjf356hjq3qboc6mreadg